NCT02569853已完成3 期
DFN-11 Injection in Episodic Migraine With or Without Aura
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 268
- 试验地点
- 16
- 主要终点
- The Percentage of Subjects in the Double-blind Period Who Are Pain Free at 2 Hours After Dosing as Reported by the Subject in the eDiary
研究概览
简要总结
Safety and Efficacy of DFN-11 in patients with episodic migraines with or without aura.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •If female, a subject must have a negative serum pregnancy test at screening, does not plan to become pregnant during the study, and is not lactating
- •If female, a subject also must have a negative urine pregnancy test at all subsequent study visits after the Screening Visit, and agree to practice a reliable form of contraception or abstinence during the study. Acceptable forms of contraception include implants, injectables, combined oral contraceptives, an intrauterine device, a vasectomized partner, an exclusively female partner, and double-barrier methods.
- •If male (with female partner), a subject must agree to practice a reliable form of contraception or abstinence during the study.
- •A history of episodic migraine who experience 2 to 6 migraine attacks a month for at least the past 12 months with no more than 14 migraine headache days per month, and with 48 hours of headache free time between migraine headaches
- •Have migraine with or without aura; if with aura, the aura cannot last longer than 60 minutes
排除标准
- •Minors, even if they are in specified study age range
- •Medication overuse headache as defined by ICHD II:
- •Opioids ≥ 10 days a month during the 90 days prior to screening
- •Combination medications (e.g., Fiorinal®) ≥ 10 days a month during the 90 days prior to screening
- •Nonsteroidal anti-inflammatory drugs (NSAIDs) or other simple medications > 14 days a month during the 90 days prior to screening
- •Triptans or ergots ≥ 10 days a month during the 90 days prior to screening
- •Subjects treated with onabotulinumtoxin A (Botox®) or other botulinum toxin treatment; or history of receiving such treatment during the 180 days prior to screening
- •On unstable dosages of migraine prophylactic medications during the 30 days prior to and through screening
- •Taking mini-prophylaxis for menstrual migraine
- •Subjects with hemiplegic or basilar migraine or other forms of neurologically complicated migraine
- •Subjects who have prolonged aura (i.e., more than 1 hour)
- •Cerebrovascular disease including but not limited to a history of stroke or transient ischemic attack (TIA)
- •A history of migralepsy (seizure following a migraine) or a concurrent diagnosis of seizure disorder
- •Subjects who cannot differentiate between a migraine headache and tension-type or cluster headache or other types of headache
- •Subjects with a history of more than occasional (based on Investigator's judgment) tension-type headache (distinct from migraine headache days count).
- •Subjects with a history of cluster headaches
- •Subjects with the diagnosis of "probable migraine" (ICHD II)
- •Ischemic coronary artery disease (CAD): including but not limited to angina pectoris, history of myocardial infarction or documented silent ischemia or coronary artery vasospasm, including Prinzmetal's angina
- •Subjects with Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders
- •Subjects with a history of congenital heart disease
- •A history of uncontrolled hypertension or screening systolic/diastolic > 140/90 mmHg
- •Have peripheral vascular disease including but not limited to ischemic bowel disease (IBD) and Raynaud's disease.
- •Any abnormal physiology and/or pathology which, in the opinion of the Investigator or Sponsor, which would be contraindicated for study participation and would not allow the objectives of the study to be met
- •Subjects who show any clinical laboratory or electrocardiogram (ECG) abnormality that in the opinion of the Investigator would endanger the subject or interfere with the study conduct. If the results of the clinical laboratory or ECG are outside of normal reference range the subject may still be enrolled but only if these findings are determined to be not clinically significant by the Investigator. This determination must be recorded in the subject's source document prior to enrolment.
- •Fridericia's corrected QT (QTcF) interval greater than 450 msec
- •Severe renal impairment (creatinine > 2 mg/dl)
- •Serum total bilirubin > 2.0 mg/dL
- •Serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphatase > 2.5 times the upper limit of normal
- •Subjects with uncontrolled diabetes mellitus, or a glycosylated hemoglobin (HbA1c) > 7.0%, or with diabetes mellitus requiring insulin
- •A history of alcohol or substance use disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Edition V (DSM-V) (including marijuana) within 1 year prior to screening
- •Current treatment with antipsychotics or use of antipsychotics within 30 days of screening
- •A history of or current neurological or psychiatric impairment, including but not limited to psychosis, current major depression, bipolar disorder or cognitive dysfunction that, in the opinion of the Investigator, would compromise data collection
- •Subjects who have received treatment with an investigational drug or device within 30 days of the screening visit or participated in a central nervous system clinical trial in the 3 months prior to screening
- •Subjects with any other medical condition that, in the judgment of the Investigator and/or Medical Monitor, would confound the objectives of the study (e.g., positive screening test for human immunodeficiency virus [HIV], hepatitis B surface antigen positive or hepatitis C positive, a known history of systemic lupus erythematosis)
- •Subjects who plan to donate blood, sperm, or oocytes during the study and for 30 days after the last dose of study medication
- •Subjects who are employees or immediate relatives of the employees of the Sponsor, any of its affiliates or partners, or of the study center
研究组 & 干预措施
DFN-11
Experimental
DFN-11 active injection upon occurrence of migraine
干预措施: DFN-11 (Drug)
Placebo
Placebo Comparator
Placebo injection upon occurrence of migraine
干预措施: Placebo (Other)
结局指标
主要结局
The Percentage of Subjects in the Double-blind Period Who Are Pain Free at 2 Hours After Dosing as Reported by the Subject in the eDiary
时间窗: 2 hours
次要结局
- The Percentage of Subjects in the Double-blind Period Who Are Pain Free at 1 Hour After Dosing as Reported by the Subject in the eDiary(1 hour)
研究者
研究点 (16)
Loading locations...
相似试验
已完成
3 期
Efficacy, Tolerability, and Safety of DFN-15Migraine HeadacheNCT03009019BioDelivery Sciences International631
已完成
3 期
Efficacy, Tolerability, and Safety Study of DFN-15Migraine HeadacheNCT03006276BioDelivery Sciences International622
终止
2 期
Pilot Study of DFN-11 Injection in Medication Overuse HeadacheMedication Overuse HeadacheNCT02583425Dr. Reddy's Laboratories Limited27
已完成
3 期
DFN-02 Open Label Safety Study in Patients With Acute MigraineAcute MigraineNCT02279082Dr. Reddy's Laboratories Limited167
已完成
2 期
Can DFN-15 Terminate Migraine With Allodynia?AllodyniaMigraine With AuraMigraine Without AuraNCT03472378Hartford Hospital51